Other adverse outcome includes genital tract infections (GTIs) and, to a lesser extent, urinary tract infections (UTIs), which may limit their utility in some patients.[10] So far no meta-analysis has evaluated the safety and efficiency in combination of SGLT2 inhibitors and insulin. The gene discussed is SLC5A2; the disease is urinary tract infection.